To develop a relevant mouse model for prostate cancer prevention research, we administered a dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo [4,5-b] 
Introduction
Prostate cancer is the most frequently diagnosed malignancy and second leading cause of cancer-related death among men in the United States (1) . Identifying the causes of this disease and developing strategies for its prevention are thus of great importance.
Epidemiologic evidence links prostate cancer incidence and mortality with consumption of red meat and animal fat (2, 3) , but the mechanism(s) by which a diet rich in red meat and fat leads to prostate cancer has not been fully established. One possible mechanism is related to the formation of heterocyclic amines (HCA) during the cooking of meat at high temperatures by grilling, broiling or frying. HCAs are well recognized as food-borne carcinogens of which 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) is the most abundant one (4) (5) (6) .
Epidemiological studies have associated PhIP exposure with increased risk for not only prostate cancer, but also colon and breast cancers (2, 7, 8) . These cancers are common in Western countries and traditionally infrequent in Asian countries; however, the incidences of such cancers are increasing in Asia, possibly due to the westernization of the diet (9, 10) .
PhIP has been shown to induce malignant lesions in rodents and primates (11) (12) (13) (14) .
Exposure of laboratory rats to PhIP in the diet has been shown to induce several types of tumors, including carcinomas of the intestine, mammary gland, and prostate (15) (16) (17) (18) . For example, large oral doses of PhIP have been shown to cause epithelial cell damage, inflammation, prostatic intraepithelial neoplasia (PIN) and carcinomas in the rat prostate (11, 12, 16, 17) . PhIP also induces lymphoid tissue tumors in mice (19) , but its induction of prostate cancer has never been reported in mice.
In studying carcinogenesis and its prevention, animal models relevant to human cancers are essential. A dietary carcinogen-induced prostate cancer model in mice, however, is not available. A possible reason for the absence of PhIP-induced prostate cancer in the mouse is due to the lack of an efficient enzyme system to activate PhIP. Initial metabolic activation of PhIP is carried out mainly by cytochrome P450 (CYP) enzymes, in particular CYP1A2 (20) . Studies have shown that human CYP1A2 preferentially activates PhIP via N 2 -hydroxylation (20) , which leads to the eventual formation of an ultimate carcinogen (Fig. 1) .
The mouse Cyp1a2, however mainly catalyzes the 4′-hydroxylation of PhIP, which is a detoxification pathways. Therefore, we used CYP1A-humanized (hCYP1A) mice, which express human CYP1A1 and CYP1A2 and are deficient in murine Cyp1a1 and Cyp1a2 (21) ,
to develop mouse models that are relevant to human carcinogenesis. It is anticipated that the increased metabolic activation of PhIP in hCYP1A mice would result in a greater carcinogenic effect than in wild-type mice. We recently demonstrated the induction of colon cancer in hCYP1A mice at as early as 6 weeks after a single oral dose of PhIP (200mg/kg body weight) and treatment with dextran sulfate sodium (1.5% in drinking fluid) (22) . The success in the development of this colon carcinogenesis model encouraged us to develop a PhIP-induced prostate carcinogenesis model.
There is strong evidence that prostatic inflammation and oxidative stress contribute to human prostatic carcinogenesis (23) (24) (25) (26) (27) . Injury to the prostate epithelium elicits a stereotypical stress and regenerative response that can promote the development of cancer (25, 28) . Molecular changes such as overexpression of cyclooxygenase-2 and p16, and down-regulation of p27, p63, PTEN and NKX3.1 have been observed in human prostate lesions (24) . Glutathione S-transferase P1 (GSTP1) is silenced through promoter methylation in subsets of cells (29) . The continued proliferation of genetically unstable luminal cells and accumulation of genomic changes are thought to lead to progression towards invasive carcinoma (24, 30) .
In this study, we demonstrated that administration of a single oral dose of PhIP to the hCYP1A mice induces prostate lesions and molecular alterations that resemble many features of human prostate carcinogenesis. In this report, we describe the development and
Materials and methods

Chemicals
PhIP was purchased from Toronto Research Chemicals (North York, Ontario, Canada) with a purity of over 99%. Before use, PhIP was dissolved in 20% (v/v) dimethyl sulfoxide (DMSO) in milliQ water (with HCl added to allow the PhIP to dissolve). Other chemicals were of the highest grade commercially available.
Animals and genotypes
Male and female Cyp1a2/Cyp1a1 tm2Dwn Tg (CYP1A1, CYP1A2)1Dwn/DwnJ and C57BL/6J mice (Cyp1a1, Cyp1a2) were purchased from Jackson Laboratories (Bar Harbor, ME) and used as founders to establish homozygous breeding colonies in our animal facility, as previously described (22) . All mice were housed in our animal facility in accordance with protocol number 02-027 approved by the Rutgers University Institutional Animal Care and Use Committee. All mice were maintained under standard 12 hour light/12 hour dark cycles with water and diet provided ad libitum unless otherwise specified.
Animal treatments and sample collection
Twenty hCYP1A-mice and ten wild-type mice were treated with a single dose of PhIP second experiment, hCYP1A mice were treated with a single dose of PhIP and then divided into two groups: AIN 76A diet and the high-fat stress diet (Research Diets, New Brunswick, NJ). The high-fat stress diet was previously designed by Newmark et al. (31) based on the AIN76A diet, by increasing the fat (corn oil) content to 40% of the calories and decreasing the contents of calcium, vitamin D 3 and phosphate to 0.5 mg/g, 0.11 IU/g, and 3.6 mg/g, respectively. The mice were sacrificed 24-38 weeks after PhIP treatment.
Histopathological analysis
After fixation in formalin, the entire prostate lobes (anterior, dorso-lateral complex, and ventral) were embedded in paraffin wax and serially sectioned at 4-µm.
Histopathological analyses of the entire prostate lobes were performed on multiple sections per block.
Lesions were identified as inflammation, atrophy, PIN and carcinoma according to the criteria commonly used to score prostate lesions in different transgenic mouse models (32, 33) . The areas with inflammation were expressed as percentages of the total luminal area. 
Statistical analysis
One-way analysis of variance (ANOVA) followed by Dunnett's test was used for comparison of differences between treatment groups and the control group. Student's t-test was used to determine the difference between two groups. For comparisons of lesions incidence, Fisher's exact test was used. Differences were considered statistically significant when p < 0.05 in two-tailed comparisons. 
Results
Administration of PhIP leads to prostate carcinogenesis in hCYP1A mice.
To assess the carcinogenic action of PhIP, hCYP1A mice and wild-type mice were given a single dose of PhIP (200mg/kg body weight) by oral gavage. After the treatment with PhIP, there was an initial slight drop in body weight of the hCYP1A and wild-type mice, but after a week the mice resumed normal growth.
The histopathological lesions of the dorso-lateral, ventral and anterior prostate glands were analyzed. Special attention was paid to the dorso-lateral prostate (DLP), which is considered to correspond to the human peripheral prostate zone, the most common site of human prostate cancer (30, 34) . Representative examples are shown in In the ventral prostate glands, the PIN lesions were less severe than those in DLG and some were associated with inflammation (Supplemental Fig. 2 ). In the anterior prostate glands, HgPIN lesions were infrequent. No abnormalities were observed in the pelvic lymph nodes. Tumor development was not observed in other organs: the small intestine, colon, lung, liver, kidney, lymph nodes, or spleen in PhIP-treated hCYP1A-mice.
High-fat diet accelerates PhIP-induced prostate carcinogenesis.
The mice on the high-fat stress diet had a 26% higher body weight than those on the AIN76A diet (32.9g vs. 26.2g on average) when sacrificed on Week 27. The high-fat stress diet appeared to accelerate lesion development (Table 1) . HgPIN lesions were observed in mice on the high-fat stress diet as early as week 24, with papillary proliferations filling about 75% of the glandular lumen (Fig. 2H) , and at week 31, showing papillary epithelial cell growth filling almost 90% of the glandular lumen (Fig. 2I) . The HgPIN lesions at week 38 showed cribriform and tufting epithelial growth patterns and marked cellular atypia with features consistent with carcinoma in situ (Fig. 2J-L) . In contrast, in 6 PhIP-treated hCYP1A mice fed the standard (low-fat) AIN76A diet, most lesions were LgPIN ( differences in HgPIN incidence and extent between hig-fat stress diet-fed mice and mice on control diet at Week 24-27 were highly significant (Table 1 ). This result suggests that the high-fat stress diet promotes prostate carcinogenesis in PhIP-treated hCYP1A mice.
Key molecular changes in human prostate cancer are found in PhIP-induced lesions in hCYP1A mice.
Androgen receptor (AR) is expressed in epithelial cells of human normal prostate, PIN, and carcinomas (30) . Positive nuclear staining was found in the luminal prostate epithelial cells in untreated mice (Fig.3A) and PhIP-induced LgPIN (Fig. 3B) and HgPIN (Fig. 3C) . Compared to the level in normal epithelial cells, AR protein immunostaining intensities were progressively higher at weeks 30 and 40 (Fig. 3D ). This result is consistent with the upregulation of AR commonly found in human prostate cancer (35) .
p63, a homolog of the p53 tumor suppressor, is a marker for prostate basal cells (36) .
Basal cells with p63 positive staining were seen along the basement membrane surrounding DLG epithelium of untreated mice (Fig. 3E) . p63 positive basal cells in the DLG were reduced in number and distributed aberrantly in the PhIP-induced LgPIN at week 30 ( Fig. 3F) and week 40 (Fig. 3G) . Quantitative analysis showed that the number of p63 positive cells decreased with time (Fig. 3H) . Absence of basal cells is a hallmark of most epithelia malignancies and it is a major diagnostic criterion for human prostate cancer (36) ; similarly, we observed loss of p63-expressing basal cells in the PhIP-induced prostate lesions in our mouse model. PTEN is a tumor suppressor that is frequently lost at advanced stages of many human malignancies, including prostate cancer (30) . We found uniform PTEN expression in the normal prostate glands (Fig. 3I) , partial loss of PTEN expression in the epithelial cells in LgPIN lesions at week 30 (Fig. 3J) (Fig. 3K) . Quantitative analysis showed that the PTEN-staining intensity was significantly lower at week 30 and appeared even lower at week 40 ( Fig. 3L) GSTP1 is a detoxifying enzyme, and the changes of its expression have been studied extensively in human prostate carcinomas (37) . GSTP1 expression was elevated in epithelial cells in atrophic DLG of PhIP-treated hCYP1A mice at week 20 as compared to the control group (Fig. 4B) . However, loss of GSTP1 expression was observed in LgPIN and HgPIN at week 30 (Fig. 4C) . In HgPIN at week 40, extensive or complete loss of GSTP1 expression was observed (Fig. 4D) . The percentage of GSTP1-positive cells was decreased significantly in HgPIN (Fig. 4E) . In anterior prostate HgPIN, extensive loss of GSTP1 expression was also observed at week 50 (data not shown).
E-Cadherin is an epithelial cell adhesion molecule involved in the maintenance of the normal tissue architecture and its dysregulation is strongly associated with human prostate cancer progression (38, 39) . In untreated mice, a high level of E-cadherin was found uniformly on plasma membrane of luminal epithelial cells (Fig. 5A) . In PhIP-treated hCYP1A mice, partial loss of E-cadherin membrane expression occurred in LgPIN lesions at week 30 (Fig. 5B ). E-Cadherin membrane expression was further reduced in HgPIN epithelial cells, with heterogeneous expression occurring at week 40 (Fig. 5C ).
Quantification of E-cadherin membrane-staining intensity in DLG showed that E-cadherin expression was reduced on week 30 and appeared to be further reduced at week 40 (Fig. 5D ).
To assess whether the loss of expression of E-cadherin and GSTP1 was associated with hypermethylation of the CpG islands in the promoter regions of these genes, we used methylation-specific qPCR to quantitate CpG island methylation status using DNA samples Fig. 3 ). The variation in Gstp1/2 CpG island methylation observed is probably due to the heterogeneous distribution of GSTP1-negative and -positive cells because we were not able to selectively dissect the area containing cells of interest. These preliminary data suggest that the promoter hypermethylation is involved in the loss of expression of Ecadherin and GSTP1, and the conclusion needs to be confirmed in future studies by bisulfate genomic sequencing.
The expression of DNMT1 is upregulated in PhIP-induced prostate lesions.
The loss of GSTP1 expression has been attributed to the silencing of the Gstp1 gene by hypermethylation of the CpG islands located in Gstp1/2 gene, and such hypermethylation has been observed frequently during the development of carcinoma (29, (40) (41) (42) (43) (44) . Therefore, we examined the expression of DNMT1. DNMT1 was expressed at low levels in a small number of prostate epithelial cells in untreated mice (Fig. 5E) 5H ). Taken together, the increase of DNMT1 and the time-dependent loss of E-cadherin and GSTP1 expression suggest that gene silencing by promoter hypermethylation is involved in the PhIP-induced prostate carcinogenesis in hCYP1A mice.
Oxidative stress is increased in the PhIP-induced prostate lesions.
To examine the possible involvement of oxidative stress in prostate carcinogenesis, we used a DNA oxidative product, 8-oxo-dG, as a marker. Low levels of basal 8-oxo-dG nuclear staining was observed in DLG epithelial cells of untreated mice (Fig. 5I) . PTEN gene mutation or to epigenetic mechanisms remains to be investigated. The presently observed initial overexpression and subsequent loss of expression of GSTP1, closely resemble the alterations in expression of this important enzyme in human prostatic cancer development (40) . Similarly, the expression of E-cadherin was down-regulated during the PhIP-induced carcinogenesis process, as seen in human prostate cancer (38, 39) . The silencing of GSTP1 and E-cadherin is likely to be caused by DNA hypermethylation (Supplemental Fig. 2) , a notion also supported by the observed induction of DNMT1 expression. In preliminary studies, we found elevated levels of DNMT1 as early as on 1 and 3 days after PhIP administration (data not shown). It is not known whether the elevated level of DNMT1 continues to weeks 30 and 40 or not. If not, DNMT1 could be induced at the later stage, possibly by inflammation and resultant oxidative stress.
Our finding that PhIP induces prostate carcinogenesis in hCYP1A mice, but not in the wild-type mice, illustrates the role of the human CYP1A2 in the activation of PhIP in vivo and further strengthens the concept that PhIP is a human prostate carcinogen. It has been established that PhIP is activated by CYP1A2 and N-acetyl transferase (or sulfotransferase) to an ultimate carcinogen, which reacts with DNA to form DNA-adducts (45, 46) . The DNAadducts conceivably lead to oncogenic mutations that may be the driving force of carcinogenesis (46) . Based on our results, we propose that epigenetic changes involving DNMT1 induction and gene silencing by DNA hypermethylation are also key events in the PhIP-induced prostate carcinogenesis.
In the present study, prostate carcinogenesis is induced in hCYP1A mice by a single oral dose of PhIP at 200 mg/kg (i.e., about 3 mg per mouse). This dose is much lower than the dietary doses used previously in a rat model of HgPIN and carcinomas (12, 16) , in which 100 and 400 ppm of PhIP in the diet was fed to rats for a period of 12 months (12, 16 
it is not surprising that the lower dose of PhIP was effective to induce prostate carcinogenesis in hCYP1A mice. In this study, we observed the early stages of prostate cancer development, which are not as advanced as some of the more aggressive, well-established, geneticallyengineered mouse models for prostate cancer (30, 47) . These models help to demonstrate the roles of designated oncogenes or tumor suppressor genes in prostate carcinogenesis, but the molecular events which trigger these genetic changes are not known. Our present model offers the opportunity to discover early molecular events that lead to these known oncogenic changes.
The roles of high-fat diet and obesity in contributing to prostate cancer are complicated and have remained inconclusive (48) , but a recent meta-analysis has showed obesity is a risk factor of prostate cancer-specific mortality and its recurrence following initial treatment (49) . Our present study suggests that a high-fat stress diet promotes the development of prostate cancer. This result is consistent with the epidemiological observation that a Western-style diet is associated with risk of prostate cancer (3, 48, 50) .
We used the high-fat stress diet, which also contained lower levels of calcium and vitamin D than the AIN76A diet (31) . The high-fat stress diet was designed by Newmark et al. (31) 
